Efficacy and Adverse Events of Intermittent Androgen Deprivation Therapy versus Continuos Androgen Deprivation Therapy on Localized and Metastatic Prostate Cancer: A Meta-Analysis

Abstract

To evaluate clinical data from published trials on efficacy and adverse events of intermittent androgen deprivation therapy (IAD) and continuous androgen deprivatin therapy (CAD). This study searched Medline, Sience direct and the Cochrane Library through August 2016 without year restriction but only english journal were included suplemented using Preferred Reporting Items for Systematic Reviews and Meta-analysis of Observational Studies in Epidemiology Guidelines. Result: 10 Studies were identified and up to 4403 patients were pooled. When compared to CAD, IAD was not statistically difference in term of overall mortality and 3 years PSA progression. But when compared to CAD, IAD was statistically better than CAD in the term reduce pain burden. Conclusions: This study conclude that the efficacy between CAD and IAD was not significant different. IAD is better to minimize pain as adverse events than CAD.